Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
about
The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic BackgroundHepatocellular carcinoma and non-alcoholic steatohepatitis: The state of playClinical features of pediatric nonalcoholic fatty liver disease: a need for increased awareness and a consensus for screening.Obesity, nutrition, and liver disease in childrenNon-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?Nanotoxicity overview: nano-threat to susceptible populationsRecommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic SteatohepatitisProgression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.Osteocalcin protects against nonalcoholic steatohepatitis in a mouse model of metabolic syndrome.Lactoferrin dampens high-fructose corn syrup-induced hepatic manifestations of the metabolic syndrome in a murine modelHerbal adaptogens combined with protein fractions from bovine colostrum and hen egg yolk reduce liver TNF-α expression and protein carbonylation in Western diet feeding in ratsNicotinamide ameliorates palmitate-induced ER stress in hepatocytes via cAMP/PKA/CREB pathway-dependent Sirt1 upregulationDicer1/miR-29/HMGCR axis contributes to hepatic free cholesterol accumulation in mouse non-alcoholic steatohepatitis.Modern approach to the clinical management of non-alcoholic fatty liver diseaseNonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective.Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control studySurgical treatment of nonalcoholic fatty liver disease in severely obese patientsPharmacological inhibition of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity.Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.Plasma levels of homocysteine and cysteine increased in pediatric NAFLD and strongly correlated with severity of liver damage.Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitisNovel insights into the function and dynamics of extracellular matrix in liver fibrosis.Fluorescence imaging for a noninvasive in vivo toxicity-test using a transgenic silkworm expressing green fluorescent proteinChemical inhibition of fatty acid absorption and cellular uptake limits lipotoxic cell death.Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis.Exercise training improves liver steatosis in miceStrategies, models and biomarkers in experimental non-alcoholic fatty liver disease researchEvaluation of Methionine Content in a High-Fat and Choline-Deficient Diet on Body Weight Gain and the Development of Non-Alcoholic Steatohepatitis in Mice.Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease.NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.Redox nanoparticles as a novel treatment approach for inflammation and fibrosis associated with nonalcoholic steatohepatitis.Fatty Acid Transport Proteins: Targeting FATP2 as a Gatekeeper Involved in the Transport of Exogenous Fatty Acids.Hepatitis C Virus-Induced Monocyte Differentiation Into Polarized M2 Macrophages Promotes Stellate Cell Activation via TGF-βHepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat.Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar.Early to Phase II drugs currently under investigation for the treatment of liver fibrosis.Free fatty acids, not triglycerides, are associated with non-alcoholic liver injury progression in high fat diet induced obese rats.
P2860
Q26744380-36D68BE3-F489-4D7D-A2B0-6D4D0C825DF4Q26764911-2D28C15B-3BDC-4565-80C0-768C07076D61Q26859406-9C1E57BF-FF67-4B3B-B6D5-688CEB035E4CQ27002523-9020B31E-603F-4319-8B24-5989BD003C17Q27006992-8EFB624E-73B9-4483-85CD-A483007D3538Q28383369-2B6D5827-6613-4D1D-B028-E9F4C5E53580Q28607750-9F6CD89A-6E1B-4999-841F-1C3A13FD460BQ30375693-A1062A8C-95D4-43AB-A5D6-4A2187222351Q33569709-11858B7E-F4AA-40F1-A8FD-E14E3BD436DEQ33591862-4C9B287B-EEFD-42A1-9F17-0C553ABD4990Q33597943-18870BF7-DC11-43C6-B1F9-498FF1474DF4Q33731432-9C5B03DD-C2F3-4699-8635-10B6FAD1FC9CQ33759921-B7DF316E-B9EE-488A-BEA3-3643E09F2DA9Q33886923-74364C9D-EE4B-40C1-956F-E5DFF168CE3EQ34412650-037B5258-ACC8-48E8-A880-E7654DF475A7Q34414807-26EF6295-639C-4824-92D5-DE8B8E95CF7FQ34446294-32FECB35-757C-43AB-B3F6-79C6EC275CA3Q34458652-6B60D9D7-895F-4A76-90D9-5265AA692FCDQ34560114-B40CC6AA-CEE9-41DB-9864-202457695344Q34589677-E69FBB86-9ECB-4127-BF86-46766864B72DQ34685694-9F0B3266-5093-4263-8140-413930302CAEQ35086412-51D4345A-B6BD-4212-BE96-DDF1C2EB6AB7Q35622533-1267B282-3BDD-4FAB-9207-A78365C41337Q35711100-ECAE294E-CC10-42D3-AF57-69E166759DFAQ35783450-BBB7E694-FF2D-4464-89A5-4EDB54FF3267Q35868386-D668678F-836C-48BC-8AD6-F76348A7D6AAQ35923163-8CD0938A-5465-4661-A72A-D1129B9DB460Q36129673-0D7B78FA-AE02-4272-AAB2-5190D28E474AQ36159376-14392225-B132-4D7E-BDA1-E8DCD697F548Q36293897-D5F070F6-0D88-454F-92F9-111C4FC86695Q36673866-8D9400D7-ED85-48C7-9A6B-0614DFB5F216Q36740555-9FDB16B1-8AC8-4BCA-A894-90722B479D63Q37013381-D6A37373-02BF-4BA6-94B5-0D57A4723D02Q37102291-417D0EEF-D96F-49BA-AD7F-2FE56472F5B7Q37296716-C7504BDA-260F-415C-9E71-1C88C7D2EDF7Q37501044-EBE918C5-7BCE-4982-A36E-24C5383E99D5Q38160948-83C995D1-00DA-41C9-8F6F-055396BB0A7EQ38218544-165F012D-BD74-4312-8325-EE5492E14DC6Q38303313-2CFF26CD-42E5-4794-92A5-A69FC8D7A7BDQ38365321-340C0200-EC54-4C3F-B373-91497FE2A373
P2860
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
@en
type
label
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
@en
prefLabel
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
@en
P2860
P356
P1476
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches
@en
P2093
Detlef Schuppan
P2860
P356
10.1111/JGH.12212
P478
28 Suppl 1
P577
2013-08-01T00:00:00Z